Rare disease leadership Sobi is a global biopharma focused on rare diseases with a strong track record in haemophilia and an expanding portfolio, signaling ongoing demand for specialized therapies and potential partnerships or co-development opportunities.

Strong revenue base With 2024 revenue of SEK 26 billion and a mid-market revenue range globally, Sobi demonstrates financial scale that supports larger deals, market expansion, and long-term collaborations across regions.

Global reach, local data Sobi operates across Europe, North America, the Middle East, Asia and Australia and presents new clinical and real-world data at major conferences, indicating opportunities for value-based discussions, payer partnerships, and data-driven market access strategies.

Patient engagement awards Recognized for patient engagement excellence and Unite4Rare initiatives, Sobi shows a strong commitment to patient-centric programs, opening doors for partnerships in patient support, digital health tools, and outcome-focused services.

Innovation and regulation Active plans to challenge market standards (e.g., efforts around gout therapies and pegcetacoplan data) combined with regulatory interactions suggest opportunities for strategic collaborations in drug development, regulatory science, and novel treatment pathways.